Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma
- 12 May 2015
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 26 (8), 1754-1759
- https://doi.org/10.1093/annonc/mdv230
Abstract
To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for PUC in 10 referral centers between 1993 and 2012. Kaplan–Meier analysis with log-rank testing was used to investigate the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean: 32 months; interquartile range: 5–48). Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy (ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery (P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of neoadjuvant treatment was significantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS (P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005). In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without ACH.Keywords
This publication has 12 references indexed in Scilit:
- Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinomaWorld Journal of Urology, 2015
- MP65-09 IMPACT OF PERIOPERATIVE CHEMOTHERAPY ON SURVIVAL IN PATIENTS WITH ADVANCED PRIMARY URETHRAL CANCER: RESULTS OF THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMAJournal of Urology, 2015
- Combined Chemoradiation as Primary Treatment for Invasive Male Urethral CancerJournal of Urology, 2015
- EAU Guidelines on Primary Urethral CarcinomaEuropean Urology, 2013
- ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the BladderEuropean Urology, 2012
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologistsUrologic Oncology: Seminars and Original Investigations, 2012
- Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial CarcinomaEuropean Urology, 2012
- Incidence and survival of rare urogenital cancers in EuropeEuropean Journal Of Cancer, 2011
- Diagnostic algorithm for papillary urothelial tumors in the urinary bladderVirchows Archiv, 2008
- Incidence of primary urethral carcinoma in the United StatesUrology, 2006